Clinical Trials Logo

Sclerosis, Systemic clinical trials

View clinical trials related to Sclerosis, Systemic.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04647890 Completed - Clinical trials for Scleroderma, Systemic

Effects of FT011 in Systemic Sclerosis

Start date: July 19, 2021
Phase: Phase 2
Study type: Interventional

FT011 is an anti-fibrotic drug that is being tested as a treatment for scleroderma. This study is being conducted to see what the body does to the drug (pharmacokinetics), and what the drug does to the body (pharmacodynamics).

NCT ID: NCT01532869 Completed - Sclerosis, Systemic Clinical Trials

A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis

Start date: March 2012
Phase: Phase 3
Study type: Interventional

This multicenter, randomized, double-blind, placebo-controlled, two-arm, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with systemic sclerosis. Patients will be randomized to receive either RoActemra/Actemra 162 mg subcutaneously weekly or placebo for 48 weeks. From Week 49 to Week 96, all patients will receive open-label RoActemra/Actemra 162 mg subcutaneously weekly. Anticipated time on study treatment is 96 weeks.